Tandem Diabetes Care (NASDAQ:TNDM) Rating Increased to Hold at Wall Street Zen

Key Points

• Tandem Diabetes Care has been upgraded from a "sell" to a "hold" rating by Wall Street Zen, reflecting a stabilization in analyst sentiment towards the stock.
• Recent reports have revealed mixed adjustments to the stock's price targets; UBS decreased its target from $20 to $17, while Canaccord Genuity maintained a "buy" rating with a price target of $24.
• The company reported a loss of $0.48 EPS for the last quarter, missing estimates, though revenue rose by 8.5% year-over-year.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Other equities research analysts also recently issued research reports about the company. UBS Group reduced their target price on Tandem Diabetes Care from $20.00 to $17.00 and set a "neutral" rating on the stock in a report on Thursday, August 7th. Piper Sandler cut Tandem Diabetes Care from an "overweight" rating to a "neutral" rating and dropped their price target for the company from $30.00 to $14.00 in a research note on Thursday, August 7th. Barclays dropped their price target on Tandem Diabetes Care from $53.00 to $51.00 and set an "overweight" rating for the company in a research note on Friday, August 8th. Wells Fargo & Company dropped their price target on Tandem Diabetes Care from $20.00 to $13.00 and set an "equal weight" rating for the company in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $24.00 price target on shares of Tandem Diabetes Care in a research note on Monday, September 29th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of "Hold" and a consensus price target of $22.19.

Tandem Diabetes Care Trading Down 3.3%

Shares of TNDM stock opened at $14.79 on Friday. The stock's fifty day moving average price is $12.62 and its two-hundred day moving average price is $16.44. The company has a market cap of $999.36 million, a PE ratio of -4.79 and a beta of 1.48. Tandem Diabetes Care has a fifty-two week low of $9.98 and a fifty-two week high of $38.28. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.08). The business had revenue of $240.68 million during the quarter, compared to analyst estimates of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) EPS. Equities analysts predict that Tandem Diabetes Care will post -1.68 EPS for the current fiscal year.

Insider Buying and Selling at Tandem Diabetes Care

In related news, CFO Leigh Vosseller bought 13,720 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $10.89 per share, with a total value of $149,410.80. Following the transaction, the chief financial officer directly owned 25,580 shares in the company, valued at approximately $278,566.20. This trade represents a 115.68% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO John F. Sheridan bought 10,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were bought at an average cost of $10.23 per share, with a total value of $102,300.00. Following the completion of the transaction, the chief executive officer owned 106,327 shares in the company, valued at $1,087,725.21. The trade was a 10.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TNDM. Assetmark Inc. lifted its stake in shares of Tandem Diabetes Care by 42.9% in the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock valued at $34,000 after purchasing an additional 525 shares during the period. CWM LLC lifted its stake in shares of Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company's stock valued at $52,000 after purchasing an additional 2,025 shares during the period. Brooklyn Investment Group lifted its stake in shares of Tandem Diabetes Care by 417.8% in the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after purchasing an additional 2,741 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 186.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company's stock valued at $78,000 after purchasing an additional 2,717 shares during the period. Finally, State of Wyoming lifted its stake in shares of Tandem Diabetes Care by 49.1% in the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company's stock valued at $86,000 after purchasing an additional 1,471 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.